title: Acute promyelocytic leukaemia with t(15;17) following treatment of Hodgkin's disease--a report of 4 cases.
abstract: BACKGROUND
  Therapy-related acute myeloid leukemia (t-AML) is a recognized entity complicating successful therapy for Hodgkin's disease (HD) and other neoplasias after many years. This risk appears to be related to cumulative exposure to alkylating agents and procarbazine, while drugs affecting DNA--topoisomerase II, such as epipodophyllotoxins and anthracyclines, are also associated with t-AML developing after a much shorter latent period.
  
  
  METHODS
  Of 56 patients with t-AML or myelodysplasia seen in our institutes during the period 1980-1994 we encountered 5 patients with acute promyelocytic leukemia (APL) all of whom had t(15;17). Four of these had been treated for HD with both chemotherapy and radiotherapy, and one with radiotherapy alone.
  
  
  RESULTS
  To the best of our knowledge these appear to be the first cases of t-AML in HD with cytogenetically proven t(15;17). Similarly to other cases of t-APL reported after therapy for neoplasias other than HD, these patients also have a relatively favorable prognosis as seen in de-novo APL.
  
  
  CONCLUSIONS
  Although rare, t-APL should be added to the list of late complications of therapy for HD.
authors.affiliation: Department of Haematology, Hadassah Medical Center, Jerusalem, Israel.
authors.forename: S
authors.initials: S
authors.lastname: Gillis
authors.forename: O
authors.initials: O
authors.lastname: Sofer
authors.forename: O
authors.initials: O
authors.lastname: Zelig
authors.forename: E J
authors.initials: EJ
authors.lastname: Dann
authors.forename: H
authors.initials: H
authors.lastname: Lotan
authors.forename: D
authors.initials: D
authors.lastname: Ben Yehuda
authors.forename: R
authors.initials: R
authors.lastname: Isacson
authors.forename: E A
authors.initials: EA
authors.lastname: Rachmilewitz
authors.forename: I
authors.initials: I
authors.lastname: Ben-Bassat
authors.forename: A
authors.initials: A
authors.lastname: Polliack
mesh_terms: D000328:Adult; D003131:Combined Modality Therapy / Q000009:adverse effects; D005260:Female; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D007621:Karyotyping; D015473:Leukemia, Promyelocytic, Acute / Q000175:diagnosis / Q000209:etiology* / Q000235:genetics; D008297:Male; D016609:Neoplasms, Second Primary / Q000209:etiology* / Q000235:genetics; D011379:Prognosis; D012189:Retrospective Studies; D014178:Translocation, Genetic